Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Developing a paediatric drug formulary for the Netherlands.
van der Zanden TM, de Wildt SN, Liem Y, Offringa M, de Hoog M; Dutch Paediatric Pharmacotherapy Expertise Network NKFK (Nederlands Kenniscentrum voor Farmacotherapie bij Kinderen). van der Zanden TM, et al. Arch Dis Child. 2017 Apr;102(4):357-361. doi: 10.1136/archdischild-2016-311674. Epub 2016 Oct 31. Arch Dis Child. 2017. PMID: 27799154 Review.
Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial.
de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Pasqua OD, Tibboel D, Ceci A, de Wildt SN; GAPP consortium. de Leeuw TG, et al. Trials. 2019 Jan 15;20(1):49. doi: 10.1186/s13063-018-3169-3. Trials. 2019. PMID: 30646965 Free PMC article.
Correction to: Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial.
de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Della Pasqua O, Tibboel D, Ceci A, de Wildt SN; GAPP consortium. de Leeuw TG, et al. Trials. 2019 Jun 20;20(1):368. doi: 10.1186/s13063-019-3519-9. Trials. 2019. PMID: 31221222 Free PMC article.
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework.
van der Zanden TM, Mooij MG, Vet NJ, Neubert A, Rascher W, Lagler FB, Male C, Grytli H, Halvorsen T, de Hoog M, de Wildt SN. van der Zanden TM, et al. Clin Pharmacol Ther. 2021 Oct;110(4):952-965. doi: 10.1002/cpt.2336. Epub 2021 Jul 29. Clin Pharmacol Ther. 2021. PMID: 34145575 Free PMC article.
14 results